Real World Evidence Solutions Market by Component (Services, Disparate Data Sets (Clinical), Application (Drug and Medical Device Development and Approvals), Mode of Deployment, Revenue Model, End Users, & Region, Business Model - Global Forecast to 2029
The global Real-World Evidence Solutions market is projected to reach USD 4.5 Billion by 2029 from USD 2.0 billion in 2024, at a CAGR of 16.5% from 2024 to 2029. The growth of the market is fuelled by an upsurging shift from volume to value-based care and rise in geriatric population. Real-world evidence (RWE) holds the potential of cutting down both costs and time in the drug development process. This has resulted in a growing adoption of RWE within numerous pharmaceutical and medical device companies, leading to drive the market growth throughout the forecast period. But scarcity of skilled personnel, and absence of universally acknowledged standards or principles governing the design, execution, analysis, and reporting of Real-World Evidence (RWE) poses a significant challenge within this market.
“Real-World Evidence Solution, services segment to witness the highest growth during the forecast period.”
Based on component, the Real-World Evidence Solution market is segmented into Real-World Evidence Solution services and Real-World Evidence Solution data sets. In 2023, service segment is projected to grow at the highest CAGR during the forecast period. The service segment encompasses advanced analytic services and consulting services. These services play a crucial role in extracting meaningful patterns of information, enabling clinicians to make informed treatment decisions. Additionally, they help end users in conducting multifunctional workshops for the development of Real-World Evidence (RWE) and operational plans. Furthermore, experts in Real-World Evidence (RWE) actively communicate and collaborate with subject matter experts from pharmaceutical and medical devices companies. This collaboration aims to provide services that contribute to the formulation of intelligent strategies, ultimately driving growth the services segment throughout the forecast period.
“Drug and Development and approval segment to register the highest growth in the Real-World Evidence Solution market during the forecast period.”
Based on application, the Real-World Evidence Solution market is segmented into drug development and approvals, medical device development and approvals, post market surveillance, market access and reimbursement/coverage decision making, Clinical & regulatory decision making. The drug development and approval segment dominate the market by application. The drug development and approvals market are further bifurcated into oncology, neurology, cardiovascular diseases, immunology, and other therapeutic areas. The oncology segment holds the largest position in drug development and approval segment. This is attributed to the increasing number of clinical trials conducted on cancer drugs, and upsurging number of cancer patients across the globe drives the segmental growth. As per World Health Organization (WHO), the implementation of evidence-based prevention strategies and the avoidance of risk factors have the potential to prevent approximately 30 to 50% of cancers.
“Pharmaceutical and medical device companies’ segment to register the highest growth in the Real-World Evidence Solution market during the forecast period.”
Based on end user, the RWE solution market is segmented into pharmaceutical and medical devices companies, healthcare payers, healthcare providers, and other end-users which includes CROs, academic institutions, patient advocacy groups, and HTA agencies. In 2023 the pharmaceutical and medical device companies hold the largest share among the end users. This is due to many companies are adapting the RWE solutions to decrease the cost and time for the drug development process, as RWE data helps new drugs and new medical devices to successfully pass through the clinical trials phases.
“APAC is estimated to register the highest CAGR during the forecast period.”
In this report, the Real-World Evidence Solution market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The RWE solution market in APAC is projected to register the highest CAGR rate during the forecast period. The growth of this region is due to rise in government initiatives towards the adoption of RWE by the pharmaceutical and medical device companies. Moreover, the clinical trials in this region are very cost-effective thus increasing the number of clinical trials being conducted in this region. For instance, according to the NOVOTECH report published in May 2022, on the Evolution of Clinical Trials in the Asia Pacific Region in comparison to the US and the EU5, a total of over 70,000 new clinical trials were recorded across the APAC region, the US, and the EU5 during the analysis period from 2017 to 2021. Notably, the APAC region emerged as the primary contributor, accounting for over 50% of the trials, followed by the US with 29%, and the EU5 with 17%.
Breakdown of supply-side primary interviews, by company type, designation, and region:
This report studies the Real-World Evidence Solution market based on components, application, end user, and region. The report also analyses factors (such as drivers, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total Real-World Evidence Solution market. The report forecasts the revenue of the market segments with respect to five major regions.
Reasons to Buy the Report
This report also includes.
“Real-World Evidence Solution, services segment to witness the highest growth during the forecast period.”
Based on component, the Real-World Evidence Solution market is segmented into Real-World Evidence Solution services and Real-World Evidence Solution data sets. In 2023, service segment is projected to grow at the highest CAGR during the forecast period. The service segment encompasses advanced analytic services and consulting services. These services play a crucial role in extracting meaningful patterns of information, enabling clinicians to make informed treatment decisions. Additionally, they help end users in conducting multifunctional workshops for the development of Real-World Evidence (RWE) and operational plans. Furthermore, experts in Real-World Evidence (RWE) actively communicate and collaborate with subject matter experts from pharmaceutical and medical devices companies. This collaboration aims to provide services that contribute to the formulation of intelligent strategies, ultimately driving growth the services segment throughout the forecast period.
“Drug and Development and approval segment to register the highest growth in the Real-World Evidence Solution market during the forecast period.”
Based on application, the Real-World Evidence Solution market is segmented into drug development and approvals, medical device development and approvals, post market surveillance, market access and reimbursement/coverage decision making, Clinical & regulatory decision making. The drug development and approval segment dominate the market by application. The drug development and approvals market are further bifurcated into oncology, neurology, cardiovascular diseases, immunology, and other therapeutic areas. The oncology segment holds the largest position in drug development and approval segment. This is attributed to the increasing number of clinical trials conducted on cancer drugs, and upsurging number of cancer patients across the globe drives the segmental growth. As per World Health Organization (WHO), the implementation of evidence-based prevention strategies and the avoidance of risk factors have the potential to prevent approximately 30 to 50% of cancers.
“Pharmaceutical and medical device companies’ segment to register the highest growth in the Real-World Evidence Solution market during the forecast period.”
Based on end user, the RWE solution market is segmented into pharmaceutical and medical devices companies, healthcare payers, healthcare providers, and other end-users which includes CROs, academic institutions, patient advocacy groups, and HTA agencies. In 2023 the pharmaceutical and medical device companies hold the largest share among the end users. This is due to many companies are adapting the RWE solutions to decrease the cost and time for the drug development process, as RWE data helps new drugs and new medical devices to successfully pass through the clinical trials phases.
“APAC is estimated to register the highest CAGR during the forecast period.”
In this report, the Real-World Evidence Solution market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The RWE solution market in APAC is projected to register the highest CAGR rate during the forecast period. The growth of this region is due to rise in government initiatives towards the adoption of RWE by the pharmaceutical and medical device companies. Moreover, the clinical trials in this region are very cost-effective thus increasing the number of clinical trials being conducted in this region. For instance, according to the NOVOTECH report published in May 2022, on the Evolution of Clinical Trials in the Asia Pacific Region in comparison to the US and the EU5, a total of over 70,000 new clinical trials were recorded across the APAC region, the US, and the EU5 during the analysis period from 2017 to 2021. Notably, the APAC region emerged as the primary contributor, accounting for over 50% of the trials, followed by the US with 29%, and the EU5 with 17%.
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
- By Designation: C-level (35%), Director-level (45%), and Others (20%)
- By Region: North America (55%), Europe (20%), Asia Pacific (15%), Latin America (5%) and Middle East Africa (5%)
- IQVIA HOLDINGS INC. (North Carolina)
- Merative (Ann Arbor, MI)
- Optum Inc. (Eden Prairie)
- Icon Plc. (Dublin)
- Syneos Health (North Carolina),
- Parexel International Corporation (North Carolina)
- Thermo Fisher Scientific Inc. (North Carolina)
- LABORATORY CORPORATION OF AMERICA HOLDINGS (Burlington, North Carolina)
- Oracle (California)
- ELEVANCE HEALTH, INC. (Indiana)
- SAS Institute Inc. (North Carolina)
- Aetion Inc. (New York)
- Trinetx Llc. (Cambridge, MA)
- Trinity (Waltham)
- PerkinElmer, Inc. (Shelton, CT)
- COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION (New Jersey)
- Clinigen Group plc (London)
- Cegedim Health Data (Boulogne-Billancourt)
- Verantos (California)
- Medspace Holdings Inc. (Ohio)
- HealthVerity, Inc. (Philadelphia)
- Datavant (San Francisco, CA)
- Syapse, Inc. (San Francisco, CA)
- Tempus (Chicago, IL)
- Flatiron Health (New York)
This report studies the Real-World Evidence Solution market based on components, application, end user, and region. The report also analyses factors (such as drivers, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total Real-World Evidence Solution market. The report forecasts the revenue of the market segments with respect to five major regions.
Reasons to Buy the Report
This report also includes.
- Analysis of key drivers ( Increasing geriatric population and rise in incidences of chronic diseases, upsurging shift from volume to value-based care, and the increase in number of pharmaceutical and biopharmaceutical companies adapting the RWE), challenges (scarcity of skilled personnel, and the lack of universally accepted methodology principles and data processing infrastructure), opportunities (the rise in focus on end-to-end RWE services, and increase in emerging markets) contributing the growth of the Real-World Evidence Solution market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the Real-World Evidence Solution market.
- Market Development: Comprehensive information on the lucrative emerging markets, components, application, end-user, and region.
- Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Real-World Evidence Solution market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global real-world evidence solution Market.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
FIGURE 1 REAL-WORLD EVIDENCE SOLUTIONS MARKET
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key Industry Insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 RESEARCH METHODOLOGY DESIGN
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.3 MARKET SIZE ESTIMATION
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
2.3.1 BOTTOM-UP APPROACH
FIGURE 7 REAL-WORLD EVIDENCE SOLUTIONS MARKET: BOTTOM-UP APPROACH
2.3.2 TOP-DOWN APPROACH
FIGURE 8 REAL-WORLD EVIDENCE SOLUTIONS MARKET: TOP-DOWN APPROACH
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN REAL-WORLD EVIDENCE SOLUTIONS MARKET (2024?2029)
FIGURE 10 REAL-WORLD EVIDENCE SOLUTIONS MARKET: CAGR PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT ANALYSIS
2.7 LIMITATIONS
2.7.1 SCOPE-RELATED LIMITATIONS
2.7.2 METHODOLOGY-RELATED LIMITATIONS
2.8 RECESSION IMPACT
3 EXECUTIVE SUMMARY
FIGURE 12 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2024 VS. 2029 (USD MILLION)
FIGURE 13 REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 14 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 16 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 17 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2024 VS. 2029 (USD MILLION)
FIGURE 18 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2024 VS. 2029 (USD MILLION)
FIGURE 19 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 20 GEOGRAPHICAL SNAPSHOT OF REAL-WORLD EVIDENCE SOLUTIONS MARKET
4 PREMIUM INSIGHTS
4.1 REAL-WORLD EVIDENCE SOLUTIONS MARKET OVERVIEW
FIGURE 21 RISING GERIATRIC POPULATION AND SUBSEQUENT INCREASE IN PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
4.2 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER AND COUNTRY (2023)
FIGURE 22 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
4.3 REAL-WORLD EVIDENCE SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 23 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
4.4 REGIONAL MIX: REAL-WORLD EVIDENCE SOLUTIONS MARKET (2024?2029)
FIGURE 24 NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
4.5 REAL-WORLD EVIDENCE SOLUTIONS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES
FIGURE 25 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 26 REAL-WORLD EVIDENCE SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 2 MARKET DYNAMICS: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising geriatric population and subsequent increase in prevalence of chronic diseases
5.2.1.2 Shift from volume-based care to value-based care
5.2.1.3 Potential of RWE in reducing drug development costs and expediting drug development process
5.2.1.4 Increased R&D spending for development of new pharmaceutical products and medical devices
FIGURE 27 NUMBER OF CLINICAL TRIALS, 2015–2020
5.2.1.5 Support from regulatory bodies for use of RWE solutions
5.2.2 RESTRAINTS
5.2.2.1 Reluctance of medical practitioners and researchers to rely on real-world studies
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging markets
5.2.3.2 Increased focus on end-to-end RWE services
5.2.4 CHALLENGES
5.2.4.1 Lack of universally accepted methodology standards and data processing infrastructure
5.2.4.2 Shortage of skilled professionals
5.3 INDUSTRY TRENDS
5.3.1 EMERGING ROLE OF WEARABLE DEVICES
5.3.2 SOCIAL MEDIA-SOURCED RWE
5.3.3 RISING USE OF RWD AND RWE ACROSS PHARMACEUTICAL INDUSTRY
FIGURE 28 RECOMMENDED INVESTMENT MODEL FOR RWD AND RWE
5.3.4 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH
FIGURE 29 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH
5.3.5 INCORPORATION OF ARTIFICIAL INTELLIGENCE IN RWD MANAGEMENT
5.4 REAL-WORLD DATA SOURCES
TABLE 3 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES
5.5 ECOSYSTEM ANALYSIS
FIGURE 30 REAL-WORLD EVIDENCE SOLUTIONS MARKET: ECOSYSTEM
5.6 VALUE CHAIN ANALYSIS
FIGURE 31 REAL-WORLD EVIDENCE SOLUTIONS MARKET: VALUE CHAIN ANALYSIS
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 32 REVENUE SHIFT IN REAL-WORLD EVIDENCE SOLUTIONS MARKET
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 BARGAINING POWER OF SUPPLIERS
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 THREAT OF SUBSTITUTES
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 PRICING ANALYSIS
5.9.1 AVERAGE SELLING PRICE, BY KEY PLAYER
5.9.2 INDICATIVE PRICE OF DATA SETS
5.10 TECHNOLOGY ANALYSIS
5.10.1 KEY TECHNOLOGIES
5.10.1.1 Use of AI and ML
5.10.1.2 Blockchain technology
5.10.2 ADJACENT TECHNOLOGIES
5.10.2.1 Predictive analytics
5.10.2.2 Visualization dashboard software
5.11 TARIFF AND REGULATORY LANDSCAPE
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.2 REGULATORY ANALYSIS
5.11.2.1 North America
5.11.2.1.1 US
5.11.2.1.1.1 Case examples
5.11.2.1.2 Canada
5.11.2.2 Europe
5.11.2.3 Asia Pacific
5.11.2.3.1 China
5.11.2.3.2 Japan
5.11.2.3.3 India
5.12 PATENT ANALYSIS
5.12.1 PATENT PUBLICATION TRENDS FOR RWE SOLUTIONS
FIGURE 33 PATENT PUBLICATION TRENDS IN REAL-WORLD SOLUTIONS MARKET, 2015–2023
5.12.2 JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 34 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTES) FOR REAL-WORLD EVIDENCE SOLUTION PATENTS (JANUARY 2015–DECEMBER 2023)
TABLE 6 LIST OF PATENTS IN REAL-WORLD EVIDENCE SOLUTIONS MARKET, 2019–2023
5.13 KEY CONFERENCES AND EVENTS
TABLE 7 REAL-WORLD EVIDENCE SOLUTIONS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS
TABLE 8 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS
5.14.2 BUYING CRITERIA
FIGURE 36 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
TABLE 9 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
5.15 USE CASES/CASE STUDIES
5.15.1 OPTIMIZING RWE WITH SCIENTIFICALLY RIGOROUS DATA-AGNOSTIC APPROACH
5.15.1.1 Use case 1: Designing and building RWE dashboards and leveraging EHR and claims data
5.15.2 UTILIZING DRUG DATA AND RWD TO ENHANCE PATIENT ADHERENCE
5.15.2.1 Use case 2: Integrating specialty pharmacy and patient hub data with RWD data to investigate non-adherence factors
5.15.3 EXISTING ANALYTICS TECHNOLOGY
5.15.3.1 Use case 3: Simplifying data analytics with RWE platform
5.16 END-USER ANALYSIS
5.16.1 UNMET NEEDS
TABLE 10 UNMET NEEDS IN REAL-WORLD EVIDENCE SOLUTIONS MARKET
5.16.2 END-USER EXPECTATIONS
TABLE 11 END-USER EXPECTATIONS IN REAL-WORLD EVIDENCE SOLUTIONS MARKET
5.17 REAL-WORLD EVIDENCE SOLUTIONS BUSINESS MODEL
5.17.1 PLATFORM AS A SERVICE (PAAS) MODEL
5.17.2 DATA PROVIDER MODEL
5.17.3 CONSULTING AND SERVICES MODEL
5.17.4 COLLABORATIVE RESEARCH MODEL
6 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT
6.1 INTRODUCTION
TABLE 12 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 13 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
6.2 SERVICES
6.2.1 RISING NEED TO CONVERT DATA INTO ACTIONABLE EVIDENCE TO DRIVE DEMAND
TABLE 14 REAL-WORLD EVIDENCE SERVICES OFFERED BY KEY MARKET PLAYERS
TABLE 15 REAL-WORLD EVIDENCE SERVICES MARKET, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 16 REAL-WORLD EVIDENCE SERVICES MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
6.3 DATA SETS
TABLE 17 REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 18 REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 19 REAL-WORLD EVIDENCE DATA SETS MARKET, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 20 REAL-WORLD EVIDENCE DATA SETS MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.1 DISPARATE DATA SETS
TABLE 21 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 22 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 23 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 24 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.1.1 Clinical settings data sets
6.3.1.1.1 Increasing utilization of EHR data for trial recruitment to fuel growth
FIGURE 37 ADOPTION OF EHR, BY HOSPITAL SERVICE TYPE, 2019–2021
TABLE 25 CLINICAL SETTINGS DATA SETS OFFERED BY KEY MARKET PLAYERS
TABLE 26 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL SETTINGS DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 27 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL SETTINGS DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.1.2 Claims data sets
6.3.1.2.1 Growing need to understand economic benefits of drug reimbursement by payers to drive growth
TABLE 28 CLAIMS DATA SETS OFFERED BY KEY MARKET PLAYERS
TABLE 29 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLAIMS DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 30 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLAIMS DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.1.3 Pharmacy data sets
6.3.1.3.1 Increasing adoption of e-prescribing systems to drive growth
FIGURE 38 TOTAL E-PRESCRIPTIONS AND CONTROLLED SUBSTANCE PRESCRIPTIONS IN US (2018–2021)
TABLE 31 PHARMACY DATA SETS OFFERED BY KEY MARKET PLAYERS
TABLE 32 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACY DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 33 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACY DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.1.4 Patient-powered data sets
6.3.1.4.1 Increasing need to access opinions on diseases and treatments across social media to drive growth
TABLE 34 PATIENT-POWERED DATA SETS OFFERED BY KEY MARKET PLAYERS
TABLE 35 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PATIENT-POWERED DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 36 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PATIENT-POWERED DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.1.5 Registry-based data sets
6.3.1.5.1 Increasing number of disease registries to drive demand for registry-based data sets in evidence generation
TABLE 37 USE OF REGISTRIES FOR EVIDENCE GENERATION
TABLE 38 REGISTRY-BASED DATA SETS OFFERED BY KEY MARKET PLAYERS
TABLE 39 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR REGISTRY-BASED DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 40 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR REGISTRY-BASED DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.2 INTEGRATED DATA SETS
6.3.2.1 Increasing demand for integrated data from multiple sources to drive growth
TABLE 41 INTEGRATED DATA SETS OFFERED BY KEY MARKET PLAYERS
TABLE 42 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR INTEGRATED DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 43 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR INTEGRATED DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
7 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION
7.1 INTRODUCTION
FIGURE 39 NUMBER OF CLINICAL TRIALS (COMPLETED), BY CONDITION/DISEASE, SEPTEMBER 2022
TABLE 44 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 45 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
7.2 DRUG DEVELOPMENT & APPROVALS
TABLE 46 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 47 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 48 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 49 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY COUNTRY, 2023–2029 (USD MILLION)
7.2.1 ONCOLOGY
7.2.1.1 Growing number of clinical trials focused on cancer treatment to drive growth
TABLE 50 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 51 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2029 (USD MILLION)
7.2.2 CARDIOVASCULAR DISEASE
7.2.2.1 High prevalence of CVD to support market growth
TABLE 52 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 53 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2023–2029 (USD MILLION)
7.2.3 NEUROLOGY
7.2.3.1 Rapidly aging global population and subsequent increase in prevalence of neurological disorders to drive growth
TABLE 54 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR NEUROLOGY, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 55 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2029 (USD MILLION)
7.2.4 IMMUNOLOGY
7.2.4.1 Increasing focus on developing innovative products to drive growth
TABLE 56 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 57 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2029 (USD MILLION)
7.2.5 OTHER THERAPEUTIC AREAS
TABLE 58 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 59 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2029 (USD MILLION)
7.3 MEDICAL DEVICE DEVELOPMENT & APPROVALS
7.3.1 INCREASING RESEARCH IN MEDICAL DEVICE DEVELOPMENT TO DRIVE DEMAND
TABLE 60 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR MEDICAL DEVICE DEVELOPMENT & APPROVALS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 61 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR MEDICAL DEVICE DEVELOPMENT & APPROVALS, BY COUNTRY, 2023–2029 (USD MILLION)
7.4 POST-MARKET SURVEILLANCE
7.4.1 EXTENSIVE USE OF RWE SOLUTIONS IN POST-MARKET SURVEILLANCE TO BOOST MARKET
TABLE 62 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR POST-MARKET SURVEILLANCE, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 63 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR POST-MARKET SURVEILLANCE, BY COUNTRY, 2023–2029 (USD MILLION)
7.5 MARKET ACCESS & REIMBURSEMENT/COVERAGE DECISION-MAKING
7.5.1 GROWING USE OF RWE SOLUTIONS TO DEVELOP ECONOMIC AND BUDGET IMPACT MODELS TO FAVOR MARKET GROWTH
TABLE 64 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR MARKET ACCESS & REIMBURSEMENT/COVERAGE DECISION-MAKING, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 65 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR MARKET ACCESS & REIMBURSEMENT/COVERAGE DECISION-MAKING, BY COUNTRY, 2023–2029 (USD MILLION)
7.6 CLINICAL & REGULATORY DECISION-MAKING
7.6.1 LIMITED VALIDITY OF RANDOMIZED CONTROLLED TRIALS TO DRIVE USE OF RWE SOLUTIONS
TABLE 66 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL & REGULATORY DECISION-MAKING, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 67 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL & REGULATORY DECISION-MAKING, BY COUNTRY, 2023–2029 (USD MILLION)
8 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL
8.1 INTRODUCTION
TABLE 68 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 69 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
8.2 PAY PER USE (VALUE-BASED PRICING)
8.2.1 RISING DEMAND FOR COST-EFFECTIVE AND FLEXIBLE SOLUTIONS TO BOOST MARKET
TABLE 70 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PAY-PER-USE (VALUE-BASED PRICING) MODELS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 71 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PAY-PER-USE (VALUE-BASED PRICING) MODELS, BY COUNTRY, 2023–2029 (USD MILLION)
8.3 SUBSCRIPTION
8.3.1 RISING PREFERENCE FOR FLEXIBILITY AND SCALABILITY TO SUPPORT MARKET GROWTH
TABLE 72 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR SUBSCRIPTION MODELS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 73 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR SUBSCRIPTION MODELS, BY COUNTRY, 2023–2029 (USD MILLION)
9 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE
9.1 INTRODUCTION
TABLE 74 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 75 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
9.2 ON-PREMISE
9.2.1 ENHANCED DATA CONTROL BENEFITS TO BOOST DEMAND
TABLE 76 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 77 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY COUNTRY, 2023–2029 (USD MILLION)
9.3 CLOUD-BASED
9.3.1 INCREASED SCALABILITY AND FLEXIBILITY IN DATA COLLECTION TO DRIVE GROWTH
TABLE 78 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 79 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2023–2029 (USD MILLION)
10 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 80 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 81 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
10.2 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES
10.2.1 INCREASED R&D EXPENDITURE IN INNOVATIVE MEDICINES TO DRIVE MARKET GROWTH
TABLE 82 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 83 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2029 (USD MILLION)
10.3 HEALTHCARE PAYERS
10.3.1 INCREASED FOCUS ON OUTCOME-BASED PAYMENT MODELS TO DRIVE DEMAND
TABLE 84 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 85 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2023–2029 (USD MILLION)
10.4 HEALTHCARE PROVIDERS
10.4.1 GROWING FOCUS ON IMPROVING PROFITABILITY TO SUPPORT MARKET GROWTH
TABLE 86 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 87 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2023–2029 (USD MILLION)
10.5 OTHER END USERS
TABLE 88 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 89 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2029 (USD MILLION)
11 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 90 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2018–2022 (USD MILLION)
TABLE 91 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2023–2029 (USD MILLION)
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 40 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET SNAPSHOT
TABLE 92 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 93 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 94 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 95 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
TABLE 96 NORTH AMERICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 97 NORTH AMERICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 98 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 99 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 101 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 102 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 103 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 104 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 105 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
TABLE 106 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 107 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 108 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 109 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
11.2.2 US
11.2.2.1 US to hold largest share of North American market
TABLE 110 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 111 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
TABLE 112 US: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 113 US: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 114 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 115 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 116 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 117 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 118 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 119 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 120 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 121 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
TABLE 122 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 123 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 124 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 125 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Rising number of clinical trials in Canada to drive market
TABLE 126 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 127 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
TABLE 128 CANADA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 129 CANADA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 130 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 131 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 132 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 133 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 134 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 135 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 136 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 137 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
TABLE 138 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 139 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 140 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 141 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
TABLE 142 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 143 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 144 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 145 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
TABLE 146 EUROPE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 147 EUROPE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 148 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 149 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 150 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 151 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 152 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 153 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 154 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 155 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
TABLE 156 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 157 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 158 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 159 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 High pharmaceutical R&D spending in Germany to boost market growth
TABLE 160 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 161 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
TABLE 162 GERMANY: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 163 GERMANY: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 164 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 165 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 166 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 167 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 168 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 169 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 170 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 171 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
TABLE 172 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 173 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 174 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 175 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
11.3.3 UK
11.3.3.1 Growing adoption of HTA to support market growth
TABLE 176 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 177 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
TABLE 178 UK: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 179 UK: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 180 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 181 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 182 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 183 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 184 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 185 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 186 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 187 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
TABLE 188 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 189 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 190 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 191 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 High number of oncology clinical trials in France to drive market growth
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
FIGURE 1 REAL-WORLD EVIDENCE SOLUTIONS MARKET
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key Industry Insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 RESEARCH METHODOLOGY DESIGN
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.3 MARKET SIZE ESTIMATION
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
2.3.1 BOTTOM-UP APPROACH
FIGURE 7 REAL-WORLD EVIDENCE SOLUTIONS MARKET: BOTTOM-UP APPROACH
2.3.2 TOP-DOWN APPROACH
FIGURE 8 REAL-WORLD EVIDENCE SOLUTIONS MARKET: TOP-DOWN APPROACH
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN REAL-WORLD EVIDENCE SOLUTIONS MARKET (2024?2029)
FIGURE 10 REAL-WORLD EVIDENCE SOLUTIONS MARKET: CAGR PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT ANALYSIS
2.7 LIMITATIONS
2.7.1 SCOPE-RELATED LIMITATIONS
2.7.2 METHODOLOGY-RELATED LIMITATIONS
2.8 RECESSION IMPACT
3 EXECUTIVE SUMMARY
FIGURE 12 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2024 VS. 2029 (USD MILLION)
FIGURE 13 REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 14 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 16 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 17 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2024 VS. 2029 (USD MILLION)
FIGURE 18 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2024 VS. 2029 (USD MILLION)
FIGURE 19 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 20 GEOGRAPHICAL SNAPSHOT OF REAL-WORLD EVIDENCE SOLUTIONS MARKET
4 PREMIUM INSIGHTS
4.1 REAL-WORLD EVIDENCE SOLUTIONS MARKET OVERVIEW
FIGURE 21 RISING GERIATRIC POPULATION AND SUBSEQUENT INCREASE IN PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
4.2 ASIA PACIFIC: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER AND COUNTRY (2023)
FIGURE 22 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
4.3 REAL-WORLD EVIDENCE SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 23 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
4.4 REGIONAL MIX: REAL-WORLD EVIDENCE SOLUTIONS MARKET (2024?2029)
FIGURE 24 NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
4.5 REAL-WORLD EVIDENCE SOLUTIONS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES
FIGURE 25 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 26 REAL-WORLD EVIDENCE SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 2 MARKET DYNAMICS: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising geriatric population and subsequent increase in prevalence of chronic diseases
5.2.1.2 Shift from volume-based care to value-based care
5.2.1.3 Potential of RWE in reducing drug development costs and expediting drug development process
5.2.1.4 Increased R&D spending for development of new pharmaceutical products and medical devices
FIGURE 27 NUMBER OF CLINICAL TRIALS, 2015–2020
5.2.1.5 Support from regulatory bodies for use of RWE solutions
5.2.2 RESTRAINTS
5.2.2.1 Reluctance of medical practitioners and researchers to rely on real-world studies
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging markets
5.2.3.2 Increased focus on end-to-end RWE services
5.2.4 CHALLENGES
5.2.4.1 Lack of universally accepted methodology standards and data processing infrastructure
5.2.4.2 Shortage of skilled professionals
5.3 INDUSTRY TRENDS
5.3.1 EMERGING ROLE OF WEARABLE DEVICES
5.3.2 SOCIAL MEDIA-SOURCED RWE
5.3.3 RISING USE OF RWD AND RWE ACROSS PHARMACEUTICAL INDUSTRY
FIGURE 28 RECOMMENDED INVESTMENT MODEL FOR RWD AND RWE
5.3.4 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH
FIGURE 29 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH
5.3.5 INCORPORATION OF ARTIFICIAL INTELLIGENCE IN RWD MANAGEMENT
5.4 REAL-WORLD DATA SOURCES
TABLE 3 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES
5.5 ECOSYSTEM ANALYSIS
FIGURE 30 REAL-WORLD EVIDENCE SOLUTIONS MARKET: ECOSYSTEM
5.6 VALUE CHAIN ANALYSIS
FIGURE 31 REAL-WORLD EVIDENCE SOLUTIONS MARKET: VALUE CHAIN ANALYSIS
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 32 REVENUE SHIFT IN REAL-WORLD EVIDENCE SOLUTIONS MARKET
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 BARGAINING POWER OF SUPPLIERS
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 THREAT OF SUBSTITUTES
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 PRICING ANALYSIS
5.9.1 AVERAGE SELLING PRICE, BY KEY PLAYER
5.9.2 INDICATIVE PRICE OF DATA SETS
5.10 TECHNOLOGY ANALYSIS
5.10.1 KEY TECHNOLOGIES
5.10.1.1 Use of AI and ML
5.10.1.2 Blockchain technology
5.10.2 ADJACENT TECHNOLOGIES
5.10.2.1 Predictive analytics
5.10.2.2 Visualization dashboard software
5.11 TARIFF AND REGULATORY LANDSCAPE
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.2 REGULATORY ANALYSIS
5.11.2.1 North America
5.11.2.1.1 US
5.11.2.1.1.1 Case examples
5.11.2.1.2 Canada
5.11.2.2 Europe
5.11.2.3 Asia Pacific
5.11.2.3.1 China
5.11.2.3.2 Japan
5.11.2.3.3 India
5.12 PATENT ANALYSIS
5.12.1 PATENT PUBLICATION TRENDS FOR RWE SOLUTIONS
FIGURE 33 PATENT PUBLICATION TRENDS IN REAL-WORLD SOLUTIONS MARKET, 2015–2023
5.12.2 JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 34 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTES) FOR REAL-WORLD EVIDENCE SOLUTION PATENTS (JANUARY 2015–DECEMBER 2023)
TABLE 6 LIST OF PATENTS IN REAL-WORLD EVIDENCE SOLUTIONS MARKET, 2019–2023
5.13 KEY CONFERENCES AND EVENTS
TABLE 7 REAL-WORLD EVIDENCE SOLUTIONS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS
TABLE 8 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS
5.14.2 BUYING CRITERIA
FIGURE 36 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
TABLE 9 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
5.15 USE CASES/CASE STUDIES
5.15.1 OPTIMIZING RWE WITH SCIENTIFICALLY RIGOROUS DATA-AGNOSTIC APPROACH
5.15.1.1 Use case 1: Designing and building RWE dashboards and leveraging EHR and claims data
5.15.2 UTILIZING DRUG DATA AND RWD TO ENHANCE PATIENT ADHERENCE
5.15.2.1 Use case 2: Integrating specialty pharmacy and patient hub data with RWD data to investigate non-adherence factors
5.15.3 EXISTING ANALYTICS TECHNOLOGY
5.15.3.1 Use case 3: Simplifying data analytics with RWE platform
5.16 END-USER ANALYSIS
5.16.1 UNMET NEEDS
TABLE 10 UNMET NEEDS IN REAL-WORLD EVIDENCE SOLUTIONS MARKET
5.16.2 END-USER EXPECTATIONS
TABLE 11 END-USER EXPECTATIONS IN REAL-WORLD EVIDENCE SOLUTIONS MARKET
5.17 REAL-WORLD EVIDENCE SOLUTIONS BUSINESS MODEL
5.17.1 PLATFORM AS A SERVICE (PAAS) MODEL
5.17.2 DATA PROVIDER MODEL
5.17.3 CONSULTING AND SERVICES MODEL
5.17.4 COLLABORATIVE RESEARCH MODEL
6 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT
6.1 INTRODUCTION
TABLE 12 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 13 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
6.2 SERVICES
6.2.1 RISING NEED TO CONVERT DATA INTO ACTIONABLE EVIDENCE TO DRIVE DEMAND
TABLE 14 REAL-WORLD EVIDENCE SERVICES OFFERED BY KEY MARKET PLAYERS
TABLE 15 REAL-WORLD EVIDENCE SERVICES MARKET, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 16 REAL-WORLD EVIDENCE SERVICES MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
6.3 DATA SETS
TABLE 17 REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 18 REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 19 REAL-WORLD EVIDENCE DATA SETS MARKET, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 20 REAL-WORLD EVIDENCE DATA SETS MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.1 DISPARATE DATA SETS
TABLE 21 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 22 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 23 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 24 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.1.1 Clinical settings data sets
6.3.1.1.1 Increasing utilization of EHR data for trial recruitment to fuel growth
FIGURE 37 ADOPTION OF EHR, BY HOSPITAL SERVICE TYPE, 2019–2021
TABLE 25 CLINICAL SETTINGS DATA SETS OFFERED BY KEY MARKET PLAYERS
TABLE 26 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL SETTINGS DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 27 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL SETTINGS DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.1.2 Claims data sets
6.3.1.2.1 Growing need to understand economic benefits of drug reimbursement by payers to drive growth
TABLE 28 CLAIMS DATA SETS OFFERED BY KEY MARKET PLAYERS
TABLE 29 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLAIMS DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 30 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLAIMS DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.1.3 Pharmacy data sets
6.3.1.3.1 Increasing adoption of e-prescribing systems to drive growth
FIGURE 38 TOTAL E-PRESCRIPTIONS AND CONTROLLED SUBSTANCE PRESCRIPTIONS IN US (2018–2021)
TABLE 31 PHARMACY DATA SETS OFFERED BY KEY MARKET PLAYERS
TABLE 32 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACY DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 33 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACY DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.1.4 Patient-powered data sets
6.3.1.4.1 Increasing need to access opinions on diseases and treatments across social media to drive growth
TABLE 34 PATIENT-POWERED DATA SETS OFFERED BY KEY MARKET PLAYERS
TABLE 35 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PATIENT-POWERED DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 36 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PATIENT-POWERED DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.1.5 Registry-based data sets
6.3.1.5.1 Increasing number of disease registries to drive demand for registry-based data sets in evidence generation
TABLE 37 USE OF REGISTRIES FOR EVIDENCE GENERATION
TABLE 38 REGISTRY-BASED DATA SETS OFFERED BY KEY MARKET PLAYERS
TABLE 39 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR REGISTRY-BASED DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 40 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR REGISTRY-BASED DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
6.3.2 INTEGRATED DATA SETS
6.3.2.1 Increasing demand for integrated data from multiple sources to drive growth
TABLE 41 INTEGRATED DATA SETS OFFERED BY KEY MARKET PLAYERS
TABLE 42 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR INTEGRATED DATA SETS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 43 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR INTEGRATED DATA SETS, BY COUNTRY, 2023–2029 (USD MILLION)
7 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION
7.1 INTRODUCTION
FIGURE 39 NUMBER OF CLINICAL TRIALS (COMPLETED), BY CONDITION/DISEASE, SEPTEMBER 2022
TABLE 44 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 45 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
7.2 DRUG DEVELOPMENT & APPROVALS
TABLE 46 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 47 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 48 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 49 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY COUNTRY, 2023–2029 (USD MILLION)
7.2.1 ONCOLOGY
7.2.1.1 Growing number of clinical trials focused on cancer treatment to drive growth
TABLE 50 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 51 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2029 (USD MILLION)
7.2.2 CARDIOVASCULAR DISEASE
7.2.2.1 High prevalence of CVD to support market growth
TABLE 52 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 53 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2023–2029 (USD MILLION)
7.2.3 NEUROLOGY
7.2.3.1 Rapidly aging global population and subsequent increase in prevalence of neurological disorders to drive growth
TABLE 54 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR NEUROLOGY, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 55 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2029 (USD MILLION)
7.2.4 IMMUNOLOGY
7.2.4.1 Increasing focus on developing innovative products to drive growth
TABLE 56 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 57 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2029 (USD MILLION)
7.2.5 OTHER THERAPEUTIC AREAS
TABLE 58 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 59 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2029 (USD MILLION)
7.3 MEDICAL DEVICE DEVELOPMENT & APPROVALS
7.3.1 INCREASING RESEARCH IN MEDICAL DEVICE DEVELOPMENT TO DRIVE DEMAND
TABLE 60 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR MEDICAL DEVICE DEVELOPMENT & APPROVALS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 61 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR MEDICAL DEVICE DEVELOPMENT & APPROVALS, BY COUNTRY, 2023–2029 (USD MILLION)
7.4 POST-MARKET SURVEILLANCE
7.4.1 EXTENSIVE USE OF RWE SOLUTIONS IN POST-MARKET SURVEILLANCE TO BOOST MARKET
TABLE 62 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR POST-MARKET SURVEILLANCE, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 63 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR POST-MARKET SURVEILLANCE, BY COUNTRY, 2023–2029 (USD MILLION)
7.5 MARKET ACCESS & REIMBURSEMENT/COVERAGE DECISION-MAKING
7.5.1 GROWING USE OF RWE SOLUTIONS TO DEVELOP ECONOMIC AND BUDGET IMPACT MODELS TO FAVOR MARKET GROWTH
TABLE 64 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR MARKET ACCESS & REIMBURSEMENT/COVERAGE DECISION-MAKING, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 65 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR MARKET ACCESS & REIMBURSEMENT/COVERAGE DECISION-MAKING, BY COUNTRY, 2023–2029 (USD MILLION)
7.6 CLINICAL & REGULATORY DECISION-MAKING
7.6.1 LIMITED VALIDITY OF RANDOMIZED CONTROLLED TRIALS TO DRIVE USE OF RWE SOLUTIONS
TABLE 66 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL & REGULATORY DECISION-MAKING, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 67 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLINICAL & REGULATORY DECISION-MAKING, BY COUNTRY, 2023–2029 (USD MILLION)
8 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL
8.1 INTRODUCTION
TABLE 68 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 69 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
8.2 PAY PER USE (VALUE-BASED PRICING)
8.2.1 RISING DEMAND FOR COST-EFFECTIVE AND FLEXIBLE SOLUTIONS TO BOOST MARKET
TABLE 70 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PAY-PER-USE (VALUE-BASED PRICING) MODELS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 71 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PAY-PER-USE (VALUE-BASED PRICING) MODELS, BY COUNTRY, 2023–2029 (USD MILLION)
8.3 SUBSCRIPTION
8.3.1 RISING PREFERENCE FOR FLEXIBILITY AND SCALABILITY TO SUPPORT MARKET GROWTH
TABLE 72 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR SUBSCRIPTION MODELS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 73 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR SUBSCRIPTION MODELS, BY COUNTRY, 2023–2029 (USD MILLION)
9 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE
9.1 INTRODUCTION
TABLE 74 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 75 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
9.2 ON-PREMISE
9.2.1 ENHANCED DATA CONTROL BENEFITS TO BOOST DEMAND
TABLE 76 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 77 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY COUNTRY, 2023–2029 (USD MILLION)
9.3 CLOUD-BASED
9.3.1 INCREASED SCALABILITY AND FLEXIBILITY IN DATA COLLECTION TO DRIVE GROWTH
TABLE 78 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 79 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR CLOUD-BASED MODELS, BY COUNTRY, 2023–2029 (USD MILLION)
10 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 80 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 81 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
10.2 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES
10.2.1 INCREASED R&D EXPENDITURE IN INNOVATIVE MEDICINES TO DRIVE MARKET GROWTH
TABLE 82 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 83 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 2023–2029 (USD MILLION)
10.3 HEALTHCARE PAYERS
10.3.1 INCREASED FOCUS ON OUTCOME-BASED PAYMENT MODELS TO DRIVE DEMAND
TABLE 84 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 85 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2023–2029 (USD MILLION)
10.4 HEALTHCARE PROVIDERS
10.4.1 GROWING FOCUS ON IMPROVING PROFITABILITY TO SUPPORT MARKET GROWTH
TABLE 86 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 87 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2023–2029 (USD MILLION)
10.5 OTHER END USERS
TABLE 88 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 89 REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2029 (USD MILLION)
11 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 90 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2018–2022 (USD MILLION)
TABLE 91 REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REGION, 2023–2029 (USD MILLION)
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 40 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET SNAPSHOT
TABLE 92 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 93 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 94 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 95 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
TABLE 96 NORTH AMERICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 97 NORTH AMERICA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 98 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 99 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 101 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 102 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 103 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 104 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 105 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
TABLE 106 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 107 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 108 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 109 NORTH AMERICA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
11.2.2 US
11.2.2.1 US to hold largest share of North American market
TABLE 110 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 111 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
TABLE 112 US: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 113 US: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 114 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 115 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 116 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 117 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 118 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 119 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 120 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 121 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
TABLE 122 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 123 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 124 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 125 US: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Rising number of clinical trials in Canada to drive market
TABLE 126 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 127 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
TABLE 128 CANADA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 129 CANADA: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 130 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 131 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 132 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 133 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 134 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 135 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 136 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 137 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
TABLE 138 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 139 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 140 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 141 CANADA: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
TABLE 142 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2018–2022 (USD MILLION)
TABLE 143 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 144 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 145 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
TABLE 146 EUROPE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 147 EUROPE: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 148 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 149 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 150 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 151 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 152 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 153 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 154 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 155 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
TABLE 156 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 157 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 158 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 159 EUROPE: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 High pharmaceutical R&D spending in Germany to boost market growth
TABLE 160 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 161 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
TABLE 162 GERMANY: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 163 GERMANY: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 164 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 165 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 166 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 167 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 168 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 169 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 170 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 171 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
TABLE 172 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 173 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 174 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 175 GERMANY: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
11.3.3 UK
11.3.3.1 Growing adoption of HTA to support market growth
TABLE 176 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)
TABLE 177 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)
TABLE 178 UK: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2018–2022 (USD MILLION)
TABLE 179 UK: REAL-WORLD EVIDENCE DATA SETS MARKET, BY TYPE, 2023–2029 (USD MILLION)
TABLE 180 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2018–2022 (USD MILLION)
TABLE 181 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DISPARATE DATA SETS, BY TYPE, 2023–2029 (USD MILLION)
TABLE 182 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)
TABLE 183 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 184 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)
TABLE 185 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET FOR DRUG DEVELOPMENT & APPROVALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)
TABLE 186 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2018–2022 (USD MILLION)
TABLE 187 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY REVENUE MODEL, 2023–2029 (USD MILLION)
TABLE 188 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2018–2022 (USD MILLION)
TABLE 189 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY DEPLOYMENT MODE, 2023–2029 (USD MILLION)
TABLE 190 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)
TABLE 191 UK: REAL-WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 High number of oncology clinical trials in France to drive market growth
